Guggenheim Russell Top 50® Mega Cap ETF
Johnson & Johnson’s Revenues Rose 11.5% in 4Q17
Johnson & Johnson (JNJ) reported 11.5% revenue growth to ~$20.2 billion during 4Q17 compared to revenues of ~$18.1 billion in 4Q16. JNJ surpassed its EPS and revenue estimates.
Merck & Co.’s Diabetes Products in 3Q17
The combined revenues for Januvia and Janumet decreased 2% at constant exchange rates to $1.52 billion in 3Q17 compared to $1.55 billion in 3Q16.
Johnson & Johnson’s Pharmaceutical Business Performance in 3Q17
JNJ’s pulmonary hypertension products were acquired from Actelion in 2Q17 and reported revenues of $670.0 million during 3Q17.
How Johnson & Johnson’s Medical Devices Business Performed in 3Q17
In 3Q17, JNJ’s Medical Devices business saw revenues of $6.6 billion, which is ~7% higher YoY (year-over-year) and 2% lower QoQ (quarter-over-quarter).
What Contributed to Pfizer’s Growth in 2016?
The key performers of Pfizer’s product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis from the Innovative Health business.
How Is Medtronic’s Globalization Strategy Driving Its Growth?
Medtronic’s (MDT) growth is driven by three of the company’s core strategies—therapy innovation, globalization, and economic value.
PowerShares QQQ’s Subsectors Generate Negative Returns
QQQ closed at $102.16 with a return of -1.19% on Friday, September 4, 2015, generating a loss of 3.28% for the week.